Hepatitis C virus: How viral proteins interact in human cells

May 8, 2014, Helmholtz Association of German Research Centres

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms behind inflammatory liver disease caused by hepatitis C viruses and open up new avenues for therapy development. The results are published in the specialist journal Molecular & Cellular Proteomics.

Viruses use human cells in order to multiply and spread. This process involves interactions with cellular host factors as well as virus-virus interactions. For example interactions among are essential for the assembly of newly produced infectious virions.

Interaction network explains viral mechanisms and opens up possibilities for new treatments

Hepatitis C virus (HCV) forms a precursor protein, which is processed into ten viral proteins. Scientists at the Institute of Virology at the Helmholtz Zentrum have now discovered how these proteins interact with one another and thus regulate important stages in the viral replication cycle. Shedding light on this interaction network creates a better understanding of the mechanisms underlying viral replication and pathogenesis and paves the way for new antiviral therapies.

As part of their investigations, the team led by Professor Michael Schindler, head of the working group at the Institute of Virology, applied the FACS-FRET* technique, which Schindler had developed at the Heinrich Pette Institute in Hamburg. With the aid of FACS-FRET, protein interactions in living cells can be characterized. Furthermore, it allows to unravel the relevance of certain interactions for replication. This method also enables screening for antiviral substances.

Finding new antiviral substances with few adverse effects

"Our results show how viral proteins interact within . This provides a basis for identifying new antiviral substances. We propose by specifically targeting virus-virus interactions to find drugs with low cellular toxicity. This hypothesis was already confirmed in first screenings approaches," Schindler explains. "Since our method can be applied in an interdisciplinary manner, we are also aiming to elucidate the networks of other human pathogenic viruses. For instance hepatitis B virus (HBV) or the human immunodeficiency virus (HIV)."

Infections with HCV lead to inflammation of the liver, and in up to 80 percent of cases the inflammation becomes chronic. Hepatitis C is a risk factor for the development of liver cirrhosis and liver cancer.

Explore further: Degradation of viral DNA in the cell nucleus opens new Hepatitis B treatment possibilities

More information: Hagen, N. et al. (2014), The intra viral protein interaction network of hepatitis C virus. Molecular & Cellular Proteomics, DOI: 10.1074/mcp.M113.036301

Related Stories

Degradation of viral DNA in the cell nucleus opens new Hepatitis B treatment possibilities

February 21, 2014
Scientists from the Helmholtz Zentrum München and the Technische Universität München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing ...

Researchers discover possible new target to attack flu virus

April 10, 2014
(Medical Xpress)—Scientists at The University of Texas at Austin have discovered that a protein produced by the influenza A virus helps it outwit one of our body's natural defense mechanisms. That makes the protein a potentially ...

New Chinese herbal medicine has significant potential in treating hepatitis C

April 12, 2014
Data from a late-breaking abstract presented at the International Liver Congress 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' ...

New focus to combat rising liver disease

July 26, 2013
University of Adelaide researchers are investigating how the liver responds to hepatitis C virus (HCV) and why some people can control the virus while others can't. The aim is to find better therapies to combat hepatitis ...

Recommended for you

Genetic flaw causes problems for many with hypothyroidism

October 23, 2018
With an estimated 120 million prescriptions filled each year, the thyroid medicine levothyroxine (marketed as Synthroid ) is one of the most popular prescription medicines in the United States. Most patients who suffer from ...

Collaboration yields possible treatment for rare neurodegenerative disorder

October 23, 2018
St. Jude Children's Research Hospital investigators have developed a new class of compounds that extended the lives and eased symptoms of mice with a progressive neurodegenerative human disorder. The findings appear today ...

'Game changer' tuberculosis drug cures 9 in 10

October 22, 2018
A new treatment for a drug-resistant strain of tuberculosis can cure more than 90 percent of sufferers, according to a trial hailed Monday as a "game changer" in the fight against the global killer.

AI doctor could boost chance of survival for sepsis patients

October 22, 2018
Scientists have created an artificial intelligence system that could help treat patients with sepsis.

Consuming caffeine from coffee reduces incident rosacea

October 22, 2018
(HealthDay)—Caffeine intake from coffee is inversely associated with the risk for incident rosacea, according to a study published online Oct. 17 in JAMA Dermatology.

Home-based biofeedback therapy is effective option for tough-to-treat constipation

October 22, 2018
Biofeedback therapy used at home is about 70 percent effective at helping patients learn how to coordinate and relax bowel muscles and relieve one of the most difficult-to-treat types of constipation, investigators report.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.